Alk Positive Non Small Cell Lung Cancer clinical trials

Explore recruiting alk positive non small cell lung cancer clinical trials.

Recruiting alk positive non small cell lung cancer studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Alk Positive Non Small Cell Lung Cancer trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

eXALT3: Phase 3 Randomized Study Comparing Ensartinib to Crizotinib in Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) Patients

Poland, France, Spain, Czechia, Belgium, Netherlands +1 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A study of gilteritinib in adults with advanced ALK-positive non-small cell lung cancer (NSCLC)

France, Spain

Human Pharmacology (Phase I)- Other EU CTIS Study details

Standard dosed alectinib versus Therageutic Drug Monitoring guided alectinib dosing: The Adapt Alec trial

Netherlands, France

Therapeutic use (Phase IV) EU CTIS Study details

A multicenter single-arm phase II interventional study to evaluate the activity and safety of the combination of Platinum-Pemetrexed based chemotherapy plus Lorlatinib in ALK positive Non-Small Cell Lung Cancer (NSCLC) with exclusively extracranial disease progression on Lorlatinib

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

IFCT-2101 MASTERPROTOCOL ALK A phase II randomized, open-labelled, multicenter study of safety and efficacy of brigatinib and carboplatin-pemetrexed combination therapy or brigatinib monotherapy as first-line treatment in patients with advanced ALK-positive non-small cell lung cancer

France

Therapeutic exploratory (Phase II) EU CTIS Study details

B7461006 - A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF LORLATINIB (PF-06463922) MONOTHERAPY VERSUS CRIZOTINIB MONOTHERAPY IN THE FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED ALK-POSITIVE NON-SMALL CELL LUNG CANCER

Poland, Netherlands, Belgium, Czechia, Italy, Germany +2 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Alk Positive Non Small Cell Lung Cancer trials by city

Alk Positive Non Small Cell Lung Cancer in Toronto Alk Positive Non Small Cell Lung Cancer in Vancouver Alk Positive Non Small Cell Lung Cancer in Montreal Alk Positive Non Small Cell Lung Cancer in Calgary Alk Positive Non Small Cell Lung Cancer in Edmonton Alk Positive Non Small Cell Lung Cancer in Ottawa Alk Positive Non Small Cell Lung Cancer in Winnipeg Alk Positive Non Small Cell Lung Cancer in Quebec City Alk Positive Non Small Cell Lung Cancer in Hamilton Alk Positive Non Small Cell Lung Cancer in Kitchener Alk Positive Non Small Cell Lung Cancer in London Alk Positive Non Small Cell Lung Cancer in Halifax Alk Positive Non Small Cell Lung Cancer in New York Alk Positive Non Small Cell Lung Cancer in Los Angeles Alk Positive Non Small Cell Lung Cancer in Chicago Alk Positive Non Small Cell Lung Cancer in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease